OtoSCOPE v9
- GTR Test IDHelpEach Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. When a laboratory updates a registered test, a new version number is assigned.: GTR000593050.2
- Last updated: 2023-01-13
- Test version history
Clinical testHelpIn the U.S., clinical tests must be performed under CLIA certification. When a lab uses the same methods for a test in both clinical and research settings, the test appears as two separate GTR records. for Deafness
Offered by Molecular Otolaryngology and Renal Research Laboratories
Overview
Test name
HelpThe name the laboratory assigns the test. Used as the default title of the page specific to the test.OtoSCOPE v9
This is a clinical test intended for HelpPurposes or indications for the test. Lab-provided.: Mutation Confirmation, Prognostic, Diagnosis
Click Indication tab for more information.
8-10 cc of whole blood in lavender top EDTA tubes or 10 μg DNA from whole blood (minimum concentration: 50 ng/μl), samples can be received Monday - Friday (no weekend or holiday deliveries), completed testing requisition form MUST accompany all samples - Institutional Billing or payment by Visa/Mastercard only.
Order URL HelpLink to the laboratory webpage with information about how to order this test. Please note that clicking on this link will open a new tab in your internet browser.: https://morl.lab.uiowa.edu/clinical-diagnostics/testing-menu
Specimen source
Methodology
HelpThe assay's major method category (biochemical, cytogenetic or molecular genetics); method category (i.e. enzyme assay, chromosome breakage studies, targeted mutation analysis); methodology (i.e. the name of the method used) and instruments used when performing this test.- Molecular Genetics
- DDeletion/duplication analysis
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Other
- targeted genomic enrichment and massively parallel sequencing
- CSequence analysis of the entire coding region
- Next-Generation (NGS)/Massively parallel sequencing (MPS)
- Agilent SureSelect
- targeted genomic enrichment and massively parallel sequencing
Not provided
Clinical validity
HelpHow consistently and accurately the test detects or predicts the intermediate or final outcomes of interest. Lab-provided.Not provided
Testing strategy
HelpThe lab's suggested sequence of ordering tests based on clinical scenarios. It may include information on: reflex testing including each test component, and scenarios which prompt additional components of testing; whether lab communicates interim results or automatically proceeds to further analyses; and if any components are performed in another laboratory.OtoSCOPE® uses custom-targeted sequence capture for DNA enrichment followed by massively parallel DNA sequencing. In this way, all genes known to cause NSHL, Usher syndrome, Pendred syndrome and other syndromes are sequenced at the same time. Data analysis to examine possible causative variants using our custom variant pipeline is followed by confirmation of possible variants by traditional Sanger sequencing. Data analysis is performed and results are discussed at a multidisciplinary meeting where each patient's variants are discussed individually and in the context of their unique clinical information to provide the most comprehensive diagnosis possible. These meetings are attended by clinical experts, research scientists, bioinformaticians and genetic counselors. 000 8-10 cc of whole blood in lavender top EDTA tubes or 10 μg DNA from whole blood (minimum concentration: 50 ng/μl), samples can be received Monday - Friday (no weekend or holiday deliveries), completed testing requisition form MUST accompany all samples - Institutional Billing or payment by Visa/Mastercard only.
Test services
HelpLaboratory's order or catalog code for the test (used in the order requisition form).- Custom Deletion/Duplication Testing
- Clinical Testing/Confirmation of Mutations Identified Previously
- Custom mutation-specific/Carrier testing
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.